Retreatment with TACE: The ABCR SCORE, an aid to the decision-making process

Journal of Hepatology

Volumn 62, Issue 4, 2015, Pages 855-862

  Adhoute, Xavier ^a   Penaranda, Guillaume ^b   Naude, Sebastien ^d   Raoul, Jean Luc ^e   Perrier, Herve ^a   Bayle, Olivier ^a   Monnet, Olivier ^a   Beaurain, Patrick ^a   Bazin, Christophe ^d   Pol, Bernard ^a   Folgoc, Gaelle Le ^a   Castellani, Paul ^a   Bronowicki, Jean Pierre ^c,d   Bourlière, Marc ^a  

^a HÔPITAL SAINT JOSEPH   (France)

^b Laboratoire Alphabio   (France)

^c UNIVERSITÉ DE LORRAINE   (France)

^d UNIVERSITY HOSPITAL OF NANCY   (France)

^e INSTITUT PAOLI CALMETTES   (France)

Author keywords

ABCR score; ART score; BCLC; Chemoembolization; HCC; Radiological response; TACE

Indexed keywords

ALPHA FETOPROTEIN; SORAFENIB;

ABCR SCORE; AGED; ARTICLE; ASSESSMENT OF HUMANS; BODY MASS; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; CHEMOEMBOLIZATION; CHILD PUGH SCORE; CONTROLLED STUDY; DECISION MAKING; FEMALE; FOLLOW UP; HUMAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RETREATMENT; SURVIVAL TIME; TRANSARTERIAL CHEMOEMBOLIZATION; CANCER STAGING; CARCINOMA, HEPATOCELLULAR; DECISION SUPPORT SYSTEM; FRANCE; LIVER NEOPLASMS; MIDDLE AGED; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PATHOLOGY; PROCEDURES; PROGNOSIS; PROPENSITY SCORE; RETROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA;

AGED; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; DECISION SUPPORT TECHNIQUES; FEMALE; FRANCE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; OUTCOME ASSESSMENT (HEALTH CARE); PROGNOSIS; PROPENSITY SCORE; RETREATMENT; RETROSPECTIVE STUDIES;

EID: 84926418860     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2014.11.014     Document Type: Article

References (36)

1. F.X. Bosch, J. Ribes, R. Cleries, and M. Diaz Epidemiology of hepatocellular carcinoma Clin Liver Dis 9 2005 191 211 V
2. H.B. El-Serag Hepatocellular carcinoma: an epidemiologic view J Clin Gastroenterol 35 2002 S72 S78
3. G. Fattovich, T. Stroffolini, I. Zagni, and F. Donato Hepatocellular carcinoma in cirrhosis: incidence and risk factors Gastroenterology 127 2004 S35 S50
4. K.H. Han, M. Kudo, S.L. Ye, J.Y. Choi, R.T. Poon, and J. Seong Asian consensus workshop report: expert consensus guideline for the management of intermediate and advanced hepatocellular carcinoma in Asia Oncology 81 2011 158 164
5. J.M. Llovet, C. Bru, and J. Bruix Prognosis of hepatocellular carcinoma: the BCLC staging classification Semin Liver Dis 19 1999 329 338
6. J.A. Marrero, R.J. Fontana, A. Barrat, F. Askari, H.S. Conjeevaram, and G.L. Su Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort Hepatology 41 2005 707 716
7. J.W. Park, M. Sherman, M. Colombo, L.R. Roberts, M. Schwartz, and F. Degos Observations of hepatocellular carcinoma (HCC) management patterns from the global HCC bridge study: first characterization of the full study population J Clin Oncol 30 2012 Abstr 4033
8. J. Bruix, and M. Sherman American Association for the Study of Liver D. Management of hepatocellular carcinoma: an update Hepatology 53 2011 1020 1022
9. M. Burrel, M. Reig, A. Forner, M. Barrufet, C.R. de Lope, and S. Tremosini Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design J Hepatol 56 2012 1330 1335
10. S. Senthilnathan, K. Memon, R.J. Lewandowski, L. Kulik, M.F. Mulcahy, and A. Riaz Extrahepatic metastases occur in a minority of hepatocellular carcinoma patients treated with locoregional therapies: analyzing patterns of progression in 285 patients Hepatology 55 2012 1432 1442
11. H.S. Lee, J.S. Kim, I.J. Choi, J.W. Chung, J.H. Park, and C.Y. Kim The safety and efficacy of transcatheter arterial chemoembolization in the treatment of patients with hepatocellular carcinoma and main portal vein obstruction. A prospective controlled study Cancer 79 1997 2087 2094
12. C.S. Georgiades, K. Hong, M. D'Angelo, and J.F. Geschwind Safety and efficacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis J Vasc Interv Radiol 16 2005 1653 1659
13. J. Luo, R.P. Guo, E.C. Lai, Y.J. Zhang, W.Y. Lau, and M.S. Chen Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a prospective comparative study Ann Surg Oncol 18 2011 413 420
14. G.E. Chung, J.H. Lee, H.Y. Kim, S.Y. Hwang, J.S. Kim, and J.W. Chung Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival Radiology 258 2011 627 634
15. K.M. Kim, J.H. Kim, I.S. Park, G.Y. Ko, H.K. Yoon, and K.B. Sung Reappraisal of repeated transarterial chemoembolization in the treatment of hepatocellular carcinoma with portal vein invasion J Gastroenterol Hepatol 24 2009 806 814
16. T.C. Xue, X.Y. Xie, L. Zhang, X. Yin, B.H. Zhang, and Z.G. Ren Transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a meta-analysis BMC Gastroenterol 8 2013 60
17. K. Takayasu, S. Arii, I. Ikai, M. Omata, K. Okita, and T. Ichida Liver Cancer Study Group of Japan. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients Gastroenterology 131 2006 461 469
18. C.M. Lo, H. Ngan, W.K. Tso, C.L. Liu, C.M. Lam, and R.T. Poon Randomized controlled trial of transarterial Lipiodol chemoembolization for unresectable hepatocellular carcinoma Hepatology 35 2002 1164 1171
19. J.M. Llovet, M.I. Real, X. Montana, R. Planas, S. Coll, and J. Aponte Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial Lancet 359 2002 1734 1739
20. J.M. Llovet, and J. Bruix Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival Hepatology 37 2003 429 442
21. R.S. Oliveri, J. Wetterslev, and C. Gluud Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma Cochrane Database Syst Rev 2011 CD004787
22. I. Sakamoto, N. Aso, K. Nagaoki, Y. Matsuoka, M. Uetani, and K. Ashizawa Complications associated with transcatheter arterial embolization for hepatic tumors Radiographics 18 1998 605 619
23. J.W. Chung, J.H. Park, J.K. Han, B.I. Choi, M.C. Han, and H.S. Lee Hepatic tumors: predisposing factors for complications of transcatheter oily chemoembolization Radiology 198 1996 33 40
24. M. Varela, M.I. Real, M. Burrel, A. Forner, M. Sala, and M. Brunet Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics J Hepatol 46 2007 474 481
25. J.L. Raoul, B. Sangro, A. Forner, V. Mazzaferro, F. Piscaglia, and L. Bolondi Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization Cancer Treat Rev 37 2011 212 220
26. J. Bruix, M. Reig, J. Rimola, A. Forner, M. Burrel, and R. Vilana Clinical decision making and research in hepatocellular carcinoma: pivotal role of imaging techniques Hepatology 54 2011 2238 2244
27. R. Gillmore, S. Stuart, A. Kirkwood, A. Hameeduddin, N. Woodward, and A.K. Burroughs EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization J Hepatol 55 2011 1309 1316
28. B.K. Kim, K.A. Kim, J.Y. Park, S.H. Ahn, C.Y. Chon, and K.H. Han Prospective comparison of prognostic values of modified Response Evaluation Criteria in Solid Tumours with European Association for the Study of the Liver criteria in hepatocellular carcinoma following chemoembolisation Eur J Cancer 49 2013 826 834
29. R. Lencioni, and J.M. Llovet Modified RECIST (mRECIST) assessment for hepatocellular carcinoma Semin Liver Dis 30 2010 52 60
30. J.M. Llovet, S. Ricci, V. Mazzaferro, P. Hilgard, E. Gane, and J.F. Blanc Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 2008 378 390
31. J. Bruix, J.L. Raoul, M. Sherman, V. Mazzaferro, L. Bolondi, and A. Craxi Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial J Hepatol 57 2012 821 829
32. W. Sieghart, F. Hucke, M. Pinter, I. Graziadei, W. Vogel, and C. Muller The ART of decision making: retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma Hepatology 57 2013 2261 2273
33. F. Hucke, W. Sieghart, M. Pinter, I. Graziadei, W. Vogel, and C. Müller The ART-strategy: sequential assessment of the ART score predicts outcome of patients with hepatocellular carcinoma re-treated with TACE J Hepatol 60 2014 118 126
34. M. Kudo, T. Arizumi, and K. Ueshima Assessment for retreatment (ART) score for repeated transarterial chemoembolization in patients with hepatocellular carcinoma Hepatology 59 2014 2424 2425
35. G. Antoch, G. Roelle, S.C. Ladd, H. Kuehl, T.A. Heusner, and G.C. Sotiropoulos Selective and sequential transarterial chemoembolization: survival in patients with hepatocellular carcinoma Eur J Radiol 81 2012 2290 2297
36. E. Terzi, R. Golfieri, F. Piscaglia, M. Galassi, A. Dazzi, and S. Leoni Response rate and clinical outcome of HCC after first and repeated cTACE performed "on demand" J Hepatol 57 2012 1258 1267